Mete Ergenoglu1, Nuri Yildirim2, Alkim Gulsah Sahingoz Yildirim1, Ozgur Yeniel1, Oytun Erbas3, Altug Yavasoglu4, Dilek Taskiran3, Nedim Karadadas1. 1. Department of Obstetrics and Gynecology, Ege University, Izmir, Turkey. 2. Department of Obstetrics and Gynecology, Dokuz Eylul University, Izmir, Turkey Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey nuri-yildirim@hotmail.com nuri.yildirim@deu.edu.tr. 3. Department of Physiology, Ege University, Izmir, Turkey. 4. Department of Histology and Embryology, Ege University, Izmir, Turkey.
Abstract
OBJECTIVE: To evaluate the effects of resveratrol in a rat model of polycystic ovarian syndrome (PCOS). STUDY DESIGN: After PCOS model was formed by subcutaneous dihydrotestosterone pellets, rats were randomly divided into 2 groups. The first group (n = 7) was treated with 1 mL/kg/d isotonic saline and the second group (n = 7) was treated with 10 mg/kg/d resveratrol. Seven rats were taken as controls without any medication. RESULTS: Our results showed (1) significant reduction in the number of antral follicle counts (P < .01); (2) significantly decreased plasma anti-Mullerian hormone and insulin-like growth factor 1 levels (P < .01 and P < .05, respectively); (3) significantly lower superoxide dismutase activity (P < .05); and (4) significantly increased glutathione peroxidase content (P < .01) following resveratrol treatment. CONCLUSION: Resveratrol appears to be effective in the treatment of PCOS due to its antioxidant properties. Future clinical studies with different dosages might provide useful implementations to our practice.
OBJECTIVE: To evaluate the effects of resveratrol in a rat model of polycystic ovarian syndrome (PCOS). STUDY DESIGN: After PCOS model was formed by subcutaneous dihydrotestosterone pellets, rats were randomly divided into 2 groups. The first group (n = 7) was treated with 1 mL/kg/d isotonic saline and the second group (n = 7) was treated with 10 mg/kg/d resveratrol. Seven rats were taken as controls without any medication. RESULTS: Our results showed (1) significant reduction in the number of antral follicle counts (P < .01); (2) significantly decreased plasma anti-Mullerian hormone and insulin-like growth factor 1 levels (P < .01 and P < .05, respectively); (3) significantly lower superoxide dismutase activity (P < .05); and (4) significantly increased glutathione peroxidase content (P < .01) following resveratrol treatment. CONCLUSION:Resveratrol appears to be effective in the treatment of PCOS due to its antioxidant properties. Future clinical studies with different dosages might provide useful implementations to our practice.